Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Wed, Jun 24, 2026

1 updates

4:29 PM

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

gilead.com

Tue, Jun 23, 2026

1 updates

7:45 AM

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

gilead.com

Mon, Jun 15, 2026

1 updates

4:34 PM

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

gilead.com

Fri, Jun 12, 2026

1 updates

8:30 AM

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

gilead.com

Thu, Jun 11, 2026

1 updates

8:30 AM

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

gilead.com

Mon, Jun 8, 2026

2 updates

4:35 PM

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Trial Results • Phase 3gilead.com

4:30 PM

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

gilead.com

Fri, Jun 5, 2026

1 updates

3:00 AM

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

gilead.com

Thu, Jun 4, 2026

1 updates

4:15 PM

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

gilead.com

Tue, Jun 2, 2026

1 updates

8:30 AM

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Trial Results • Phase 3gilead.com

Wed, May 27, 2026

1 updates

2:00 AM

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

Interim Data • Phase 3gilead.com

Fri, May 22, 2026

2 updates

2:00 PM

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

gilead.com

7:47 AM

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

gilead.com

Thu, May 21, 2026

3 updates

5:00 PM

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

gilead.com

9:30 AM

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

gilead.com

3:30 AM

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

gilead.com

Thu, May 14, 2026

1 updates

9:21 PM

Gilead Prices $3 Billion of Senior Unsecured Notes

gilead.com

Wed, May 13, 2026

1 updates

8:30 AM

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

gilead.com

Thu, May 7, 2026

1 updates

4:01 PM

Gilead Sciences Announces First Quarter Financial Results

gilead.com

Fri, May 1, 2026

1 updates

6:00 AM

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

gilead.com

Wed, Apr 29, 2026

1 updates

8:30 AM

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

gilead.com

Tue, Apr 28, 2026

1 updates

8:45 AM

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

gilead.com

Wed, Apr 22, 2026

1 updates

4:05 PM

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

gilead.com

Fri, Apr 17, 2026

1 updates

8:30 AM

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

gilead.com

Tue, Apr 14, 2026

1 updates

12:00 PM

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

gilead.com